Neuraxis shares are trading higher after the company announced a new CPT category I code for percutaneous electrical nerve field stimulation.
Portfolio Pulse from Benzinga Newsdesk
Neuraxis shares rose following the announcement of a new CPT category I code for percutaneous electrical nerve field stimulation, potentially enhancing the company's market position.
October 22, 2024 | 4:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Neuraxis shares increased due to the announcement of a new CPT category I code for their percutaneous electrical nerve field stimulation, which could improve market adoption and revenue.
The new CPT category I code is likely to facilitate broader adoption of Neuraxis's nerve stimulation product, potentially increasing sales and revenue. This positive development has led to a rise in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100